• Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort 

      Sarink, Danja; Schock, Helena; Johnson, Theron; Chang-Claude, Jenny; Overvad, Kim; Olsen, Anja; Tjønneland, Anne; Arveux, Patrick; Fournier, Agnès; Kvaskoff, Marina; Boeing, Heiner; Karakatsani, Anna; Trichopoulou, Antonia; La Vecchia, Carlo; Masala, Giovanna; Agnoli, Claudia; Panico, Salvatore; Tumino, Rosario; Sacerdote, Carlotta; van Gils, Carla H.; Peeters, Petra H.M.; Weiderpass, Elisabete; Agudo, Antonio; Rodríguez-Barranco, Miguel; Huerta, José María; Ardanaz, Eva; Gil, Leire; Kaw, Kay Tee; Schmidt, Julie A.; Dossus, Laure; His, Mathilde; Aune, Dagfinn; Riboli, Elio; Kaaks, Rudolf; Fortner, Renée T. (Journal article; Peer reviewed, 2018-10-22)
      <b>Background</b><br> Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to ...